Wednesday, October 24, 2012

Podcast: Scientific and Technical Challenges of Developing Contrave

In this podcast Dr. Klassen discusses the scientific and technical challenges of developing Contrave, part of the “new wave” of anti-obesity compounds driving the industry forward after nearly 13 years. He will cover the technical and scientific challenges involved in drug testing, the need for better biomarker validation and metabolic endpoint selection, the potential for discovering novel pathways and mechanisms of action for pre-existing compounds, and the major factors concerning reimbursement of weight loss drugs.

Featured Speaker: Dr. Preston Klassen
SVP & Head of Development, Orexigen Therapeutics

We announce IIR’s Innovation and Commercialization of Therapeutics for Metabolic Disorders event! The skyrocketing growth rates of both obesity and type-2 diabetes are widely recognized as public health threats. With so many unmet and ever-growing needs, this market represents possibly the last remaining opportunity for new blockbuster drugs.  It  will deliver successful strategies for the technical, regulatory and market access hurdles so your company can take the lead in this market.  For more information on the event, download the agenda. If you'd like to join us Febraury 11-13, 2012 in Baltimore, register today and mention code XP1803BLOG to save 15% off the standard rate!  









No comments: